Correlation Between Cadrenal Therapeutics, and Hillstream Biopharma

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Hillstream Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Hillstream Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Hillstream Biopharma, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Hillstream Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Hillstream Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Hillstream Biopharma.

Diversification Opportunities for Cadrenal Therapeutics, and Hillstream Biopharma

-0.69

Correlation Coefficient

Cadrenal Therapeutics,  Hillstream Biopharma

Excellent diversification

The 3 months correlation between Cadrenal and Hillstream is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Hillstream Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hillstream Biopharma and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Hillstream Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hillstream Biopharma has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Hillstream Biopharma go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Hillstream Biopharma

If you would invest  795.00  in Cadrenal Therapeutics, Common on August 31, 2024 and sell it today you would earn a total of  620.00  from holding Cadrenal Therapeutics, Common or generate 77.99% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	1.59%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Hillstream Biopharma

Cadrenal Therapeutics,

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Hillstream Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hillstream Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Hillstream Biopharma is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Cadrenal Therapeutics, and Hillstream Biopharma

The main advantage of trading using opposite Cadrenal Therapeutics, and Hillstream Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Hillstream Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hillstream Biopharma will offset losses from the drop in Hillstream Biopharma's long position.

The idea behind Cadrenal Therapeutics, Common and Hillstream Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.